DiaMedica Therapeutics Inc (DMAC)vsBeiGene, Ltd. (ONC)
DMAC
DiaMedica Therapeutics Inc
$8.20
-1.44%
HEALTHCARE · Cap: $428.17M
ONC
BeiGene, Ltd.
$365.27
-0.47%
HEALTHCARE · Cap: $39.69B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 10.7% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 64/100 (C+).
DMAC
Avoid20
out of 100
Grade: F
ONC
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DMAC.
Margin of Safety
+80.0%
Fair Value
$1758.06
Current Price
$365.27
$1392.79 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Earnings expanding 166.7% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 29.6% year-over-year
Areas to Watch
Trading at 11.5x book value
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DMAC
The strongest argument for DMAC centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 29.6% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bear Case : DMAC
The primary concerns for DMAC are Price/Book, Revenue Growth, EPS Growth.
Bear Case : ONC
The primary concerns for ONC are P/E Ratio, Altman Z-Score. A P/E of 62.9x leaves little room for execution misses.
Key Dynamics to Monitor
DMAC profiles as a value stock while ONC is a growth play — different risk/reward profiles.
DMAC carries more volatility with a beta of 0.97 — expect wider price swings.
ONC is growing revenue faster at 29.6% — sustainability is the question.
ONC generates stronger free cash flow (596M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (64/100 vs 20/100) and 29.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DiaMedica Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?